Januvia, Singulair, Advair top sites among primary care docs: study

Share this article:

Web sites for Merck's type 2 diabetes drug Januvia, Merck's asthma and allergy treatment Singulair and GlaxoSmithKline's asthma medication Advair were the top three online product destinations respectively among US primary care doctors in 2007, a new study shows.

Market research firm Manhattan Research, which coordinated the study, said the purpose of the analysis was to better determine the leading online physician destinations based on the satisfaction and number of physician visitors.

“The latest research reveals physician site traffic is spread among product sites of new and early launch stage treatments, those with clinical news coverage, and consistent with years past, products with a significant consumer advertising component,” Manhattan Research president Mark Bard said in a statement.

Rounding out the top 10 pharmaceutical product Web sites among physicians in 2007, ranked by number of US primary care physician visitors, were:

4. Pfizer's smoking-cessation aid Chantix

5. Shire's ADHD treatment Adderall XR 

6. Lilly's type 2 diabetes treatment Byetta

7. Merck's HPV vaccine Gardasil

8. Merck and Schering-Plough's joint-venture cholesterol-lowerer Vytorin

9. GlaxoSmithKline's diabetes treatment Avandia

10. McNeill's ADHD treatment Concerta

“We have seen these product sites evolve into brand gateways with visitation from physicians, healthcare professionals, and consumers and with the majority of the top 10 product sites changing from year-to-year, there is clearly a need among physicians for the most up-to-date product information,” Bard added. 

Share this article:

Email Newsletters

More in News

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds